Skip to main content
Top
Published in: Annals of Surgical Oncology 9/2009

01-09-2009 | Controversies in the Management of Hepatic Colorectal Metastases

Synchronous Colorectal Liver Metastases: Is It Time to Reconsider Traditional Paradigms of Management?

Authors: Srinevas K. Reddy, MD, Andrew S. Barbas, MD, Bryan M. Clary, MD

Published in: Annals of Surgical Oncology | Issue 9/2009

Login to get access

Abstract

Background

Patients with synchronous colorectal liver metastases (CLM) are typically treated with initial colorectal resection followed by arbitrary and prolonged courses of chemotherapy. Partial hepatectomy is considered only for patients without interval disease progression. This review describes the rationale for this treatment approach and the recent developments suggesting that this management paradigm should be reconsidered.

Results

Because asymptomatic colorectal cancer often does not lead to complications, and given the potential benefit of chemotherapy in downsizing unresectable to resectable liver disease, most patients with asymptomatic primary tumors and unresectable synchronous CLM should be first treated with chemotherapy. In contrast, initial hepatic resection should be considered for resectable synchronous CLM. Survival benefits from prehepatectomy chemotherapy have not been established. Several reports demonstrate morbidity after hepatic resection from extended durations of irinotecan- and/or oxaliplatin-based prehepatectomy chemotherapy. Although shorter treatment periods may not have these deleterious effects on subsequent hepatic resection, prospective studies reveal that most patients with supposedly aggressive disease with short treatment durations will not be identified. Moreover, a complete radiologic response to prehepatectomy chemotherapy is not only rare but also does not equate with a complete pathological response. Finally, several studies suggest that simultaneous colorectal and minor hepatic resections can performed safely with benefits in total morbidity when compared with traditional staged procedures.

Conclusions

The traditional treatment paradigm centering on the utility of prehepatectomy chemotherapy for resectable synchronous CLM should be reconsidered. Recent developments underscore the need for prospective randomized controlled trials evaluating the optimal timing of hepatectomy relative to chemotherapy.
Literature
1.
go back to reference Chafai N, Chan CLH, Bokey EL, et al. What factors influence survival in patients with unresected synchronous liver metastases after resection of colorectal cancer? Colorectal Dis. 2005;7:176–81.PubMedCrossRef Chafai N, Chan CLH, Bokey EL, et al. What factors influence survival in patients with unresected synchronous liver metastases after resection of colorectal cancer? Colorectal Dis. 2005;7:176–81.PubMedCrossRef
2.
go back to reference Rougier P, Milan C, Lazorthes F, et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Br J Surg. 1995;82:1397–400.PubMedCrossRef Rougier P, Milan C, Lazorthes F, et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Br J Surg. 1995;82:1397–400.PubMedCrossRef
3.
go back to reference Stangl R, Altendorf-Hofmann A, Charnley RM, et al. Factors influencing the natural history of colorectal liver metastases. Lancet. 1994;343:1405–10.PubMedCrossRef Stangl R, Altendorf-Hofmann A, Charnley RM, et al. Factors influencing the natural history of colorectal liver metastases. Lancet. 1994;343:1405–10.PubMedCrossRef
4.
go back to reference Al-asfoor A, Fedorowicz Z, Lodge M. Resection versus no intervention or other surgical interventions for colorectal liver metastases. Cochrane Database Syst Rev. 2008;CD006039. Al-asfoor A, Fedorowicz Z, Lodge M. Resection versus no intervention or other surgical interventions for colorectal liver metastases. Cochrane Database Syst Rev. 2008;CD006039.
5.
go back to reference Cummings FJ, Varker K, Begossi G, et al. Hepatic artery infusion in surgical therapy of hepatic metastases from colorectal cancer. J Clin Oncol. 2008;26:abstr 15077. Cummings FJ, Varker K, Begossi G, et al. Hepatic artery infusion in surgical therapy of hepatic metastases from colorectal cancer. J Clin Oncol. 2008;26:abstr 15077.
6.
go back to reference Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2008;25:4575–80.CrossRef Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2008;25:4575–80.CrossRef
7.
go back to reference Newland RC, Dent OF, Chapuis PH, et al. Clinicopathologically diagnosed residual tumour after resection for colorectal cancer: a 20-year prospective study. Cancer. 1993;72:1536–42.PubMedCrossRef Newland RC, Dent OF, Chapuis PH, et al. Clinicopathologically diagnosed residual tumour after resection for colorectal cancer: a 20-year prospective study. Cancer. 1993;72:1536–42.PubMedCrossRef
8.
go back to reference Vigano L, Ferrero A, Tesoriere RL, et al. Liver surgery for colorectal metastases: results after 10 years of follow-up, long-term survivors, late recurrences, and prognostic role of morbidity. Ann Surg Oncol. 2008;15:2458–64.PubMedCrossRef Vigano L, Ferrero A, Tesoriere RL, et al. Liver surgery for colorectal metastases: results after 10 years of follow-up, long-term survivors, late recurrences, and prognostic role of morbidity. Ann Surg Oncol. 2008;15:2458–64.PubMedCrossRef
9.
go back to reference Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection of colorectal metastases. Ann Surg. 2005;241:715–24.PubMedCrossRef Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection of colorectal metastases. Ann Surg. 2005;241:715–24.PubMedCrossRef
10.
go back to reference Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 Trial. J Clin Oncol. 2006;24:4976–82.PubMedCrossRef Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 Trial. J Clin Oncol. 2006;24:4976–82.PubMedCrossRef
11.
go back to reference Aloia TA, Vauthey JN, Loyer EM, et al. Solitary colorectal liver metastasis: resection determined outcome. Arch Surg. 2006;141:460–6.PubMedCrossRef Aloia TA, Vauthey JN, Loyer EM, et al. Solitary colorectal liver metastasis: resection determined outcome. Arch Surg. 2006;141:460–6.PubMedCrossRef
12.
go back to reference Charnsangavej C, Clary B, Fong Y, et al. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13:1261–8.PubMedCrossRef Charnsangavej C, Clary B, Fong Y, et al. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13:1261–8.PubMedCrossRef
13.
go back to reference Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist. 2008;13:51–64.PubMedCrossRef Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist. 2008;13:51–64.PubMedCrossRef
14.
go back to reference Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy. Ann Surg. 2004;240:644–58.PubMedCrossRef Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy. Ann Surg. 2004;240:644–58.PubMedCrossRef
15.
go back to reference Fortner JG, Silva JS, Cox EB, et al. Multivariate of a personal series of 247 patients with liver metastases from colorectal cancer. Ann Surg. 1984;199:317–24.PubMed Fortner JG, Silva JS, Cox EB, et al. Multivariate of a personal series of 247 patients with liver metastases from colorectal cancer. Ann Surg. 1984;199:317–24.PubMed
16.
go back to reference Yamamura T, Senda T, Akaishi O, et al. Comparative studies on treatment for liver metastases from colorectal cancer. St Marianna Med J. 1990;18:501–8. Yamamura T, Senda T, Akaishi O, et al. Comparative studies on treatment for liver metastases from colorectal cancer. St Marianna Med J. 1990;18:501–8.
17.
go back to reference Cady D, Monson DO, Swinton NW. Survival of patients after colonic resection for carcinoma with simultaneous liver metastases. Surg Gynecol Obstet. 1970;131:697–700.PubMed Cady D, Monson DO, Swinton NW. Survival of patients after colonic resection for carcinoma with simultaneous liver metastases. Surg Gynecol Obstet. 1970;131:697–700.PubMed
18.
go back to reference Blumgart LH, Allison DJ. Resection and embolization in the management of secondary hepatic tumors. World J Surg. 1982;6:32–45.PubMedCrossRef Blumgart LH, Allison DJ. Resection and embolization in the management of secondary hepatic tumors. World J Surg. 1982;6:32–45.PubMedCrossRef
19.
go back to reference Jatzko G, Wette V, Muller M, et al. Simultaneous resection of colorectal carcinoma and synchronous liver metastases in a district hospital. Int J Colorectal Dis. 1991;6:111–4.PubMedCrossRef Jatzko G, Wette V, Muller M, et al. Simultaneous resection of colorectal carcinoma and synchronous liver metastases in a district hospital. Int J Colorectal Dis. 1991;6:111–4.PubMedCrossRef
20.
go back to reference Minagawa M, Yamamoto J, Miwa S, et al. Selection criteria for simultaneous resection in patients with synchronous liver metastasis. Arch Surg. 2006;141:1006–12.PubMedCrossRef Minagawa M, Yamamoto J, Miwa S, et al. Selection criteria for simultaneous resection in patients with synchronous liver metastasis. Arch Surg. 2006;141:1006–12.PubMedCrossRef
21.
go back to reference Tebutt NC, Norman AR, Cunningham D, et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut. 2003;52:568–73.CrossRef Tebutt NC, Norman AR, Cunningham D, et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut. 2003;52:568–73.CrossRef
22.
go back to reference Scoggins CR, Meszoely IM, Blanke CD, et al. Nonoperative management of primary colorectal cancer in patients with stage IV disease. J Surg Oncol. 1999;6:651–7.CrossRef Scoggins CR, Meszoely IM, Blanke CD, et al. Nonoperative management of primary colorectal cancer in patients with stage IV disease. J Surg Oncol. 1999;6:651–7.CrossRef
23.
go back to reference Benoist S, Pautrat K, Mitry E, et al. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg. 2005;92:1155–60.PubMedCrossRef Benoist S, Pautrat K, Mitry E, et al. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg. 2005;92:1155–60.PubMedCrossRef
24.
go back to reference Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229–37.PubMedCrossRef Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229–37.PubMedCrossRef
25.
go back to reference Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.PubMedCrossRef Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.PubMedCrossRef
26.
27.
go back to reference Rivera F, Van Cutsem E, Kretzschmar A, et al. Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI, and monotherapy for mCRC: first BEATrial. Ann Oncol. 2007;18:abstr O-0025. Rivera F, Van Cutsem E, Kretzschmar A, et al. Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI, and monotherapy for mCRC: first BEATrial. Ann Oncol. 2007;18:abstr O-0025.
28.
go back to reference Tirelli U, Berretta M, Di Benedetto F, et al. Presurgical chemotherapy with FOLFOX4-regimen for patients with unresectable liver metastases from colorectal cancer. J Clin Oncol. 2008;26:abstr 15052. Tirelli U, Berretta M, Di Benedetto F, et al. Presurgical chemotherapy with FOLFOX4-regimen for patients with unresectable liver metastases from colorectal cancer. J Clin Oncol. 2008;26:abstr 15052.
29.
go back to reference Masi G, Loupakis F, Baldi G, et al. Outcome of initially unresectable metastatic colorectal cancer patients treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases. J Clin Oncol. 2008;26:abstr 4074. Masi G, Loupakis F, Baldi G, et al. Outcome of initially unresectable metastatic colorectal cancer patients treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases. J Clin Oncol. 2008;26:abstr 4074.
30.
go back to reference Wicherts DA, de Haas RJ, Adam R. Bringing unresectable liver disease to resection with curative intent. Eur J Surg Oncol. 2007;33:S42–51.PubMed Wicherts DA, de Haas RJ, Adam R. Bringing unresectable liver disease to resection with curative intent. Eur J Surg Oncol. 2007;33:S42–51.PubMed
31.
go back to reference Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004;15:933–9.PubMedCrossRef Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004;15:933–9.PubMedCrossRef
32.
go back to reference Nuzzo G, Giuliante F, Ardito F, et al. Liver resection for primary unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg. 2007;11:318–24.PubMedCrossRef Nuzzo G, Giuliante F, Ardito F, et al. Liver resection for primary unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg. 2007;11:318–24.PubMedCrossRef
33.
go back to reference Abdalla EK, Adam R, Bilchik AJ, et al. Improving resectablity of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13:1271–80.PubMedCrossRef Abdalla EK, Adam R, Bilchik AJ, et al. Improving resectablity of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13:1271–80.PubMedCrossRef
34.
go back to reference Nordlinger B, Van Cutsem E, Rougier P, et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? Eur J Cancer. 2007;43:2037–45.PubMedCrossRef Nordlinger B, Van Cutsem E, Rougier P, et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? Eur J Cancer. 2007;43:2037–45.PubMedCrossRef
35.
go back to reference Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially irresectable colorectal liver metastases: is there a possibility of cure by an oncosurgical approach? J Clin Oncol. 2008;26:abstr 4081. Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially irresectable colorectal liver metastases: is there a possibility of cure by an oncosurgical approach? J Clin Oncol. 2008;26:abstr 4081.
36.
go back to reference Adam R, Aloia T, Levi F, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol. 2007;25:4593–602.PubMedCrossRef Adam R, Aloia T, Levi F, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol. 2007;25:4593–602.PubMedCrossRef
37.
go back to reference Wagner AD, Arnold D, Grothey A, et al. Anti-angiogenic therapies for metastatic colorectal cancer: preliminary results of a systematic review and meta-analysis. J Clin Oncol. 2008;26:abstr 4060. Wagner AD, Arnold D, Grothey A, et al. Anti-angiogenic therapies for metastatic colorectal cancer: preliminary results of a systematic review and meta-analysis. J Clin Oncol. 2008;26:abstr 4060.
38.
go back to reference Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol. 2008;26:3523–9.PubMedCrossRef Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol. 2008;26:3523–9.PubMedCrossRef
39.
go back to reference Minagawa M, Yamamoto J, Kosuge T, et al. Simplified staging system for predicting the prognosis of patients with resectable liver metastasis: development and validation. Arch Surg. 2007;142:269–76.PubMedCrossRef Minagawa M, Yamamoto J, Kosuge T, et al. Simplified staging system for predicting the prognosis of patients with resectable liver metastasis: development and validation. Arch Surg. 2007;142:269–76.PubMedCrossRef
40.
go back to reference Minagawa M, Makuuchi M, Torzilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg. 2000;231:487–99.PubMedCrossRef Minagawa M, Makuuchi M, Torzilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg. 2000;231:487–99.PubMedCrossRef
41.
go back to reference Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–21.PubMedCrossRef Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–21.PubMedCrossRef
42.
go back to reference Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Cancer. 1996;77:1254–62.PubMedCrossRef Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Cancer. 1996;77:1254–62.PubMedCrossRef
43.
go back to reference Schindl M, Wigmore SJ, Currie EJ, et al. Prognostic scoring in colorectal cancer liver metastasis: development and validation. Arch Surg. 2005;140:183–9.PubMedCrossRef Schindl M, Wigmore SJ, Currie EJ, et al. Prognostic scoring in colorectal cancer liver metastasis: development and validation. Arch Surg. 2005;140:183–9.PubMedCrossRef
44.
go back to reference Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases form colorectal carcinoma. Surg Oncol Clin N Am. 2003;12:165–92.PubMedCrossRef Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases form colorectal carcinoma. Surg Oncol Clin N Am. 2003;12:165–92.PubMedCrossRef
45.
go back to reference Mala T, Bohler G, Mathisen O, et al. Hepatic resection for colorectal metastases: can preoperative scoring predict outcome? World J Surg. 2002;26:1348–53.PubMedCrossRef Mala T, Bohler G, Mathisen O, et al. Hepatic resection for colorectal metastases: can preoperative scoring predict outcome? World J Surg. 2002;26:1348–53.PubMedCrossRef
46.
go back to reference van Ooijen B, Wiggers T, Meijer S, et al. Hepatic resections for colorectal metastases in The Netherlands: a multi-institutional 10-year study. Cancer. 1992;70:28–34.PubMedCrossRef van Ooijen B, Wiggers T, Meijer S, et al. Hepatic resections for colorectal metastases in The Netherlands: a multi-institutional 10-year study. Cancer. 1992;70:28–34.PubMedCrossRef
47.
go back to reference Cady B, Jenkins RL, Steele GD, et al. Surgical margin in hepatic resection for colorectal metastases: a critical and improvable determinant of outcome. Ann Surg. 1998;227:566–71.PubMedCrossRef Cady B, Jenkins RL, Steele GD, et al. Surgical margin in hepatic resection for colorectal metastases: a critical and improvable determinant of outcome. Ann Surg. 1998;227:566–71.PubMedCrossRef
48.
go back to reference Jamison RL, Donohue JH, Nagorney DM, et al. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg. 1997;132:505–11.PubMed Jamison RL, Donohue JH, Nagorney DM, et al. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg. 1997;132:505–11.PubMed
49.
go back to reference Hughes K, Scheele J, Sugarbaker PH. Surgery for colorectal cancer metastatic to the liver: optimizing the results of treatment. Surg Clin N Am. 1989;69:339–59.PubMed Hughes K, Scheele J, Sugarbaker PH. Surgery for colorectal cancer metastatic to the liver: optimizing the results of treatment. Surg Clin N Am. 1989;69:339–59.PubMed
50.
go back to reference Hughes KS, Rosenstein RB, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of long-term survivors. Dis Colon Rectum. 1988;31:1–4.PubMedCrossRef Hughes KS, Rosenstein RB, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of long-term survivors. Dis Colon Rectum. 1988;31:1–4.PubMedCrossRef
51.
go back to reference Jenkins LT, Millikan KW, Bines SD, et al. Hepatic resection for metastatic colorectal cancer. Am Surg. 1997;63:605–10.PubMed Jenkins LT, Millikan KW, Bines SD, et al. Hepatic resection for metastatic colorectal cancer. Am Surg. 1997;63:605–10.PubMed
52.
go back to reference Doci R, Gennari L, Bignami P, et al. One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants. Br J Surg. 1991;78:797–801.PubMedCrossRef Doci R, Gennari L, Bignami P, et al. One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants. Br J Surg. 1991;78:797–801.PubMedCrossRef
53.
go back to reference Hohenberger P, Schlag PM, Gerneth T, et al. Pre- and postoperative carcinoembryonic antigen determinations in hepatic resection for colorectal metastases: predictive value and implications for adjuvant treatment based on multivariate analysis. Ann Surg. 1994;219:135–43.PubMedCrossRef Hohenberger P, Schlag PM, Gerneth T, et al. Pre- and postoperative carcinoembryonic antigen determinations in hepatic resection for colorectal metastases: predictive value and implications for adjuvant treatment based on multivariate analysis. Ann Surg. 1994;219:135–43.PubMedCrossRef
54.
go back to reference Ychou M, Hohenberger W, Thezenas S, et al. Randomized phase III trial comparing infused 5-fluorouracil/folinic acid (LV5FU) versus LV5FU + irinotecan (LV5FU + IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (LMCRC). J Clin Oncol. 2008;26:abstr LBA4013. Ychou M, Hohenberger W, Thezenas S, et al. Randomized phase III trial comparing infused 5-fluorouracil/folinic acid (LV5FU) versus LV5FU + irinotecan (LV5FU + IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (LMCRC). J Clin Oncol. 2008;26:abstr LBA4013.
55.
go back to reference Mariani P, Des Guetz G, Uzzan B, et al. Systemic or hepatic arterial chemotherapy after curative resection of liver metastases from colorectal cancer: a meta-analysis of randomized controlled trials. J Clin Oncol. 2008;26:abstr 4077. Mariani P, Des Guetz G, Uzzan B, et al. Systemic or hepatic arterial chemotherapy after curative resection of liver metastases from colorectal cancer: a meta-analysis of randomized controlled trials. J Clin Oncol. 2008;26:abstr 4077.
56.
go back to reference Iwatsuki S, Dvorchik I, Madariaga JR, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg. 1999;189:291–9.PubMedCrossRef Iwatsuki S, Dvorchik I, Madariaga JR, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg. 1999;189:291–9.PubMedCrossRef
57.
go back to reference Harmon KE, Ryan JA, Biehl TR, et al. Benefits and safety of hepatic resection for colorectal metastases. Am J Surg. 1999;177:402–4.PubMedCrossRef Harmon KE, Ryan JA, Biehl TR, et al. Benefits and safety of hepatic resection for colorectal metastases. Am J Surg. 1999;177:402–4.PubMedCrossRef
58.
go back to reference Harms J, Obst T, Thorban S, et al. The role of surgery in the treatment of liver metastases for colorectal cancer patients. Hepatogastroenterology. 1999;46:2321–8.PubMed Harms J, Obst T, Thorban S, et al. The role of surgery in the treatment of liver metastases for colorectal cancer patients. Hepatogastroenterology. 1999;46:2321–8.PubMed
59.
go back to reference Kokudo N, Seki M, Ohta H, et al. Effects of systemic and regional chemotherapy after hepatic resection for colorectal metastases. Ann Surg Oncol. 1998;5:706–12.PubMedCrossRef Kokudo N, Seki M, Ohta H, et al. Effects of systemic and regional chemotherapy after hepatic resection for colorectal metastases. Ann Surg Oncol. 1998;5:706–12.PubMedCrossRef
60.
go back to reference Bockhorn M, Frilling A, Fruhauf NR, et al. Survival of patients with synchronous and metachronous colorectal liver metastases—is there a difference? J Gastrointest Surg. 2008;12:1399–405.PubMedCrossRef Bockhorn M, Frilling A, Fruhauf NR, et al. Survival of patients with synchronous and metachronous colorectal liver metastases—is there a difference? J Gastrointest Surg. 2008;12:1399–405.PubMedCrossRef
61.
go back to reference Capussotti L, Vigano L, Ferrero A, et al. Timing of resection of liver metastases synchronous to colorectal tumor: proposal for prognosis-based decisional model. Ann Surg Oncol. 2007;14:1143–50.PubMedCrossRef Capussotti L, Vigano L, Ferrero A, et al. Timing of resection of liver metastases synchronous to colorectal tumor: proposal for prognosis-based decisional model. Ann Surg Oncol. 2007;14:1143–50.PubMedCrossRef
62.
go back to reference Lee WS, MJ Kim, SH Yun, et al. Risk factor stratification after simultaneous liver and colorectal resection for synchronous colorectal metastasis. Langenbecks Arch Surg. 2008;393:13–9.PubMedCrossRef Lee WS, MJ Kim, SH Yun, et al. Risk factor stratification after simultaneous liver and colorectal resection for synchronous colorectal metastasis. Langenbecks Arch Surg. 2008;393:13–9.PubMedCrossRef
63.
go back to reference de Santibanes E, Lassalle FB, McCormack L, et al. Simultaneous colorectal and hepatic resections for colorectal cancer: postoperative and longterm outcomes. J Am Coll Surg. 2002;195:196–202.PubMedCrossRef de Santibanes E, Lassalle FB, McCormack L, et al. Simultaneous colorectal and hepatic resections for colorectal cancer: postoperative and longterm outcomes. J Am Coll Surg. 2002;195:196–202.PubMedCrossRef
64.
go back to reference Gruenberger T, Kaczirek K, Bergmann M, et al. Progression-free survival in a phase II study of perioperative bevacizumab plus XELOX in patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26:abstr 4073. Gruenberger T, Kaczirek K, Bergmann M, et al. Progression-free survival in a phase II study of perioperative bevacizumab plus XELOX in patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26:abstr 4073.
65.
go back to reference Jonas S, Thelen A, Benckert C, et al. Extended resections of liver metastases from colorectal cancer. World J Surg. 2007;31:511–21.PubMedCrossRef Jonas S, Thelen A, Benckert C, et al. Extended resections of liver metastases from colorectal cancer. World J Surg. 2007;31:511–21.PubMedCrossRef
66.
go back to reference Figueras J, Torras J, Valls C, et al. Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon Rectum. 2007;50:478–88.PubMedCrossRef Figueras J, Torras J, Valls C, et al. Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon Rectum. 2007;50:478–88.PubMedCrossRef
67.
go back to reference Tsai MS, Su YH, Ho MC, et al. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol. 2007;14:786–94.PubMedCrossRef Tsai MS, Su YH, Ho MC, et al. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol. 2007;14:786–94.PubMedCrossRef
68.
go back to reference Wei AC, Greig PD, Grant D, et al. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol. 2006;13:668–76.PubMedCrossRef Wei AC, Greig PD, Grant D, et al. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol. 2006;13:668–76.PubMedCrossRef
69.
go back to reference Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–66.PubMedCrossRef Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–66.PubMedCrossRef
70.
go back to reference Malik HZ, Hamady ZZR, Adair R, et al. Prognositic influence of multiple hepatic metastases from colorectal cancer. Eur J Surg Oncol. 2007;33:468–73.PubMedCrossRef Malik HZ, Hamady ZZR, Adair R, et al. Prognositic influence of multiple hepatic metastases from colorectal cancer. Eur J Surg Oncol. 2007;33:468–73.PubMedCrossRef
71.
go back to reference Ercolani G, Grazi GL, Ravaioli M, et al. Liver resection for multiple colorectal metastases: influence of parenchymal involvement and total tumor volume, vs. number or location, on long-term survival. Arch Surg. 2002;137:1187–92.PubMedCrossRef Ercolani G, Grazi GL, Ravaioli M, et al. Liver resection for multiple colorectal metastases: influence of parenchymal involvement and total tumor volume, vs. number or location, on long-term survival. Arch Surg. 2002;137:1187–92.PubMedCrossRef
72.
go back to reference Bakalakos EA, Kim JA, Young DC, et al. Determinants of survival following hepatic resection for metastatic colorectal cancer. World J Surg. 1998;22:399–405.PubMedCrossRef Bakalakos EA, Kim JA, Young DC, et al. Determinants of survival following hepatic resection for metastatic colorectal cancer. World J Surg. 1998;22:399–405.PubMedCrossRef
73.
go back to reference Ohlsson B, Stenram U, Tranberg KG. Resection of colorectal liver metastases: 25-year experience. World J Surg. 1998;22:268–77.PubMedCrossRef Ohlsson B, Stenram U, Tranberg KG. Resection of colorectal liver metastases: 25-year experience. World J Surg. 1998;22:268–77.PubMedCrossRef
74.
go back to reference Ambiru S, Miyazaki M, Isono T, et al. Hepatic resection for colorectal metastases: analysis of prognostic factors. Dis Colon Rectum. 1999;42:632–9.PubMedCrossRef Ambiru S, Miyazaki M, Isono T, et al. Hepatic resection for colorectal metastases: analysis of prognostic factors. Dis Colon Rectum. 1999;42:632–9.PubMedCrossRef
75.
go back to reference Laurent C, Cunha AS, Couderc P, et al. Influence of postoperative morbidity on long-term survival following liver resection for colorectal metastases. Br J Surg. 2003;90:1131–6.PubMedCrossRef Laurent C, Cunha AS, Couderc P, et al. Influence of postoperative morbidity on long-term survival following liver resection for colorectal metastases. Br J Surg. 2003;90:1131–6.PubMedCrossRef
76.
go back to reference Bradley AL, Chapman WC, Wright JK, et al. Surgical experience with hepatic colorectal metastasis. Am Surg. 1999;65:560–6.PubMed Bradley AL, Chapman WC, Wright JK, et al. Surgical experience with hepatic colorectal metastasis. Am Surg. 1999;65:560–6.PubMed
77.
go back to reference Nagashima I, Takada T, Matsuda K, et al. A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection. J Hepatobiliary Pancreat Surg. 2004;11:79–83.PubMedCrossRef Nagashima I, Takada T, Matsuda K, et al. A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection. J Hepatobiliary Pancreat Surg. 2004;11:79–83.PubMedCrossRef
78.
go back to reference Nicoli N, Casaril A, Mangiante G, et al. Surgical treatment for liver metastases from colorectal carcinoma: results of 228 patients. Hepatogastroenterology. 2004;51:1810–4.PubMed Nicoli N, Casaril A, Mangiante G, et al. Surgical treatment for liver metastases from colorectal carcinoma: results of 228 patients. Hepatogastroenterology. 2004;51:1810–4.PubMed
79.
go back to reference Seifert JK, Bottger TC, Weigel TF, et al. Prognostic factors following liver resection for hepatic metastases from colorectal cancer. Hepatogastroenterology. 2000;47:239–46.PubMed Seifert JK, Bottger TC, Weigel TF, et al. Prognostic factors following liver resection for hepatic metastases from colorectal cancer. Hepatogastroenterology. 2000;47:239–46.PubMed
80.
go back to reference Tanaka K, Shimada H, Ueda M, et al. Long-term characteristics of 5-year survivors after liver resection for colorectal metastases. Ann Surg Oncol. 2007;14:1336–46.PubMedCrossRef Tanaka K, Shimada H, Ueda M, et al. Long-term characteristics of 5-year survivors after liver resection for colorectal metastases. Ann Surg Oncol. 2007;14:1336–46.PubMedCrossRef
81.
go back to reference Parks R, Gonen M, Kemeny N, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg. 2007;204:753–63.PubMedCrossRef Parks R, Gonen M, Kemeny N, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg. 2007;204:753–63.PubMedCrossRef
82.
go back to reference Nordlinger B, Sorbye H, Glemelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for respectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet. 2008;371:1007–16.PubMedCrossRef Nordlinger B, Sorbye H, Glemelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for respectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet. 2008;371:1007–16.PubMedCrossRef
83.
go back to reference Gruenberger B, Scheithauer, Punzengruber R, et al. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer. 2008;8:120–7.PubMedCrossRef Gruenberger B, Scheithauer, Punzengruber R, et al. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer. 2008;8:120–7.PubMedCrossRef
84.
go back to reference Taylor I. Adjuvant chemotherapy after resection of liver metastases from colorectal cancer. Eur J Cancer. 2008;44:1198–201.PubMedCrossRef Taylor I. Adjuvant chemotherapy after resection of liver metastases from colorectal cancer. Eur J Cancer. 2008;44:1198–201.PubMedCrossRef
85.
go back to reference Tanaka K, Adam R, Shimada H, et al. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg. 2003;90:963–9.PubMedCrossRef Tanaka K, Adam R, Shimada H, et al. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg. 2003;90:963–9.PubMedCrossRef
86.
go back to reference Hewes JC, Dighe S, Morris RW, et al. Preoperative chemotherapy and the outcome of liver resection for colorectal metastases. World J Surg. 2007;31:353–64.PubMedCrossRef Hewes JC, Dighe S, Morris RW, et al. Preoperative chemotherapy and the outcome of liver resection for colorectal metastases. World J Surg. 2007;31:353–64.PubMedCrossRef
87.
go back to reference Allen PJ, Kemeny N, Jarnagin W, et al. Importance of neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg. 2003;7:109–15.PubMedCrossRef Allen PJ, Kemeny N, Jarnagin W, et al. Importance of neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg. 2003;7:109–15.PubMedCrossRef
88.
go back to reference Mentha G, Majno P, Terraz S, et al. Treatment strategies for the management of advanced colorectal liver metastases detected synchronously with the primary tumour. Eur J Surg Oncol. 2007;33:S76–83.PubMed Mentha G, Majno P, Terraz S, et al. Treatment strategies for the management of advanced colorectal liver metastases detected synchronously with the primary tumour. Eur J Surg Oncol. 2007;33:S76–83.PubMed
89.
go back to reference Mentha G, Majno PE, Andres A, et al. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg. 2006;93:872–8.PubMedCrossRef Mentha G, Majno PE, Andres A, et al. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg. 2006;93:872–8.PubMedCrossRef
90.
go back to reference Kornprat P, Jarnagin WR, Gonen M, et al. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol. 2007;14:1151–60.PubMedCrossRef Kornprat P, Jarnagin WR, Gonen M, et al. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol. 2007;14:1151–60.PubMedCrossRef
91.
go back to reference Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy. Ann Surg. 2004;240:1052–64.PubMedCrossRef Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy. Ann Surg. 2004;240:1052–64.PubMedCrossRef
92.
go back to reference Lambert LA, Colacchio TA, Barth RJ. Interval hepatic resection of colorectal metastases improves patient selection. Arch Surg. 2000;135:473–9.PubMedCrossRef Lambert LA, Colacchio TA, Barth RJ. Interval hepatic resection of colorectal metastases improves patient selection. Arch Surg. 2000;135:473–9.PubMedCrossRef
93.
go back to reference Yoshidome H, Kimura F, Shimizu H, et al. Interval period tumor progression: does delayed hepatectomy detect occult metastases in synchronous colorectal liver metastases? J Gastrointest Surg. 2008;12:1391–8.PubMedCrossRef Yoshidome H, Kimura F, Shimizu H, et al. Interval period tumor progression: does delayed hepatectomy detect occult metastases in synchronous colorectal liver metastases? J Gastrointest Surg. 2008;12:1391–8.PubMedCrossRef
94.
go back to reference Kopetz S, Vauthey JN. Perioperative chemotherapy for resectable hepatic metastases. Lancet. 2008;371:963–4.PubMedCrossRef Kopetz S, Vauthey JN. Perioperative chemotherapy for resectable hepatic metastases. Lancet. 2008;371:963–4.PubMedCrossRef
95.
go back to reference Shimizu Y, Yasui K, Sano T, et al. Validity of observation interval for synchronous hepatic metastases of colorectal cancer: changes in hepatic and extrahepatic metastatic foci. Langenbecks Arch Surg. 2008;393:181–4.PubMedCrossRef Shimizu Y, Yasui K, Sano T, et al. Validity of observation interval for synchronous hepatic metastases of colorectal cancer: changes in hepatic and extrahepatic metastatic foci. Langenbecks Arch Surg. 2008;393:181–4.PubMedCrossRef
96.
go back to reference Gruenberger G, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colon cancer. J Clin Oncol. 2008;26:1830–5.PubMedCrossRef Gruenberger G, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colon cancer. J Clin Oncol. 2008;26:1830–5.PubMedCrossRef
97.
go back to reference Bouganim N, Ang C, Kavan P, et al. Perioperative bevacizumab containing chemotherapy for colorectal liver metastases. J Clin Oncol. 2008;26:abstr 15073. Bouganim N, Ang C, Kavan P, et al. Perioperative bevacizumab containing chemotherapy for colorectal liver metastases. J Clin Oncol. 2008;26:abstr 15073.
98.
go back to reference Berry SR, Van Cutsem E, Kretzschmar A, et al. Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: first BEAT. J Clin Oncol. 2008;26:abstr 4025. Berry SR, Van Cutsem E, Kretzschmar A, et al. Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: first BEAT. J Clin Oncol. 2008;26:abstr 4025.
99.
go back to reference White RR, Schwartz LH, Munoz JA, et al. Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases. J Surg Oncol. 2008;97:601–4.PubMedCrossRef White RR, Schwartz LH, Munoz JA, et al. Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases. J Surg Oncol. 2008;97:601–4.PubMedCrossRef
100.
go back to reference Elias D, Youssef O, Sideris L, et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol. 2004;86:4–9.PubMedCrossRef Elias D, Youssef O, Sideris L, et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol. 2004;86:4–9.PubMedCrossRef
101.
go back to reference Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008;26:1635–41.PubMedCrossRef Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008;26:1635–41.PubMedCrossRef
102.
go back to reference Benoit S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24:3939–45.CrossRef Benoit S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24:3939–45.CrossRef
103.
go back to reference Tan MCB, Linehan DC, Hawkins WG, et al. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathological response. J Gastrointest Surg. 2007;11:1112–9.PubMedCrossRef Tan MCB, Linehan DC, Hawkins WG, et al. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathological response. J Gastrointest Surg. 2007;11:1112–9.PubMedCrossRef
104.
go back to reference Covas A, Amininejad L, Lucidi V, et al. Evaluation of the correlation of complete metabolic response with 18-FDG PET scan and complete pathologic response induced by neoadjuvant chemotherapy for colorectal liver metastases. J Clin Oncol. 2008;26:abstr 4070. Covas A, Amininejad L, Lucidi V, et al. Evaluation of the correlation of complete metabolic response with 18-FDG PET scan and complete pathologic response induced by neoadjuvant chemotherapy for colorectal liver metastases. J Clin Oncol. 2008;26:abstr 4070.
105.
go back to reference Conlon R, Jacobs M, Dasgupta D, et al. The value of intraoperative ultrasound during hepatic resection compared with improved preoperative magnetic resonance imaging. Eur J Ultrasound. 2003;16:211–6.PubMedCrossRef Conlon R, Jacobs M, Dasgupta D, et al. The value of intraoperative ultrasound during hepatic resection compared with improved preoperative magnetic resonance imaging. Eur J Ultrasound. 2003;16:211–6.PubMedCrossRef
106.
go back to reference Jarnagin WR, Bach AM, Winston CB, et al. What is the yield of intraoperative ultrasonography during partial hepatectomy for malignant disease? J Am Coll Surg. 2001;192:577–83.PubMedCrossRef Jarnagin WR, Bach AM, Winston CB, et al. What is the yield of intraoperative ultrasonography during partial hepatectomy for malignant disease? J Am Coll Surg. 2001;192:577–83.PubMedCrossRef
107.
go back to reference Wildi SM, Gubler C, Hany T, et al. Intraoperative sonography in patients with colorectal cancer and resectable liver metastases on preoperative FDG-PET-CT. J Clin Ultrasound. 2008;36:20–6.PubMedCrossRef Wildi SM, Gubler C, Hany T, et al. Intraoperative sonography in patients with colorectal cancer and resectable liver metastases on preoperative FDG-PET-CT. J Clin Ultrasound. 2008;36:20–6.PubMedCrossRef
108.
go back to reference Tamandl D, Herberger B, Gruenberger B, et al. Adequate preoperative staging rarely leads to a change of intraoperative strategy in patients undergoing surgery for colorectal cancer liver metastases. Surgery. 2008;143:648–57.PubMedCrossRef Tamandl D, Herberger B, Gruenberger B, et al. Adequate preoperative staging rarely leads to a change of intraoperative strategy in patients undergoing surgery for colorectal cancer liver metastases. Surgery. 2008;143:648–57.PubMedCrossRef
109.
go back to reference Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460–6.PubMedCrossRef Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460–6.PubMedCrossRef
110.
go back to reference Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1–7.PubMedCrossRef Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1–7.PubMedCrossRef
111.
go back to reference Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006;24:4983–90.PubMedCrossRef Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006;24:4983–90.PubMedCrossRef
112.
go back to reference Vauthey JN, Pawlik TM, Ribero D, et al. Chemothearpy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065–72.PubMedCrossRef Vauthey JN, Pawlik TM, Ribero D, et al. Chemothearpy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065–72.PubMedCrossRef
113.
go back to reference Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247:118–24.PubMedCrossRef Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247:118–24.PubMedCrossRef
114.
go back to reference Pawlik TM, Olino K, Gleisner AL, et al. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg. 2007;11:860–8.PubMedCrossRef Pawlik TM, Olino K, Gleisner AL, et al. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg. 2007;11:860–8.PubMedCrossRef
115.
go back to reference Kandutsch S, Klinger M, Hacker S, et al. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. Eur J Surg Oncol. 2008;34:1231–6.PubMed Kandutsch S, Klinger M, Hacker S, et al. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. Eur J Surg Oncol. 2008;34:1231–6.PubMed
116.
go back to reference Mehta NN, Ravikumar R, Coldham CA, et al. Effect of preoperative chemotherapy on liver resection for colorectal liver metastases. Eur J Surg Oncol. 2008;34:782–6.PubMed Mehta NN, Ravikumar R, Coldham CA, et al. Effect of preoperative chemotherapy on liver resection for colorectal liver metastases. Eur J Surg Oncol. 2008;34:782–6.PubMed
117.
go back to reference Julie C, Lutz MP, Aust D, et al. Pathological analysis of hepatic injury after oxaliplatin-based neoadjuvant chemotherapy of colorectal cancer liver metastases: results of the EORTC Intergroup phase III study 40983. Paper presented at the 2007 Gastrointestinal Cancers Symposium, abstr 241. Julie C, Lutz MP, Aust D, et al. Pathological analysis of hepatic injury after oxaliplatin-based neoadjuvant chemotherapy of colorectal cancer liver metastases: results of the EORTC Intergroup phase III study 40983. Paper presented at the 2007 Gastrointestinal Cancers Symposium, abstr 241.
118.
go back to reference Fernandez FG, Ritter J, Goodwin JW, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005;200:845–53.PubMedCrossRef Fernandez FG, Ritter J, Goodwin JW, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005;200:845–53.PubMedCrossRef
119.
go back to reference Reddy SK, Morse MA, Hurwitz HI, et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg. 2008;206:96–106.PubMedCrossRef Reddy SK, Morse MA, Hurwitz HI, et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg. 2008;206:96–106.PubMedCrossRef
120.
go back to reference Klinger M, Kandutsch S, Hacker S, et al. Patterns of hepatotoxicity after chemotherapy for colorectal cancer metastases. J Clin Oncol. 2008;226:abstr 4082. Klinger M, Kandutsch S, Hacker S, et al. Patterns of hepatotoxicity after chemotherapy for colorectal cancer metastases. J Clin Oncol. 2008;226:abstr 4082.
121.
go back to reference Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007;110:2761–7.PubMedCrossRef Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007;110:2761–7.PubMedCrossRef
122.
go back to reference Aussilhou B, Faivre S, Lepille v, et al. Preoperative bevacizumab may impair liver hypertrophy of the future remnant liver after a portal vein occlusion in patients undergoing major resections of colorectal liver metastases. J Clin Oncol. 2008;26:abstr 4081. Aussilhou B, Faivre S, Lepille v, et al. Preoperative bevacizumab may impair liver hypertrophy of the future remnant liver after a portal vein occlusion in patients undergoing major resections of colorectal liver metastases. J Clin Oncol. 2008;26:abstr 4081.
123.
go back to reference Reddy SK, Pawlik TM, Zorzi D, et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol. 2007;14:3481–91.PubMedCrossRef Reddy SK, Pawlik TM, Zorzi D, et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol. 2007;14:3481–91.PubMedCrossRef
124.
go back to reference Capussotti L, Ferrero A, Vigano L, et al. Major liver resections synchronous with colorectal surgery. Ann Surg Oncol. 2007;14:195–201.PubMedCrossRef Capussotti L, Ferrero A, Vigano L, et al. Major liver resections synchronous with colorectal surgery. Ann Surg Oncol. 2007;14:195–201.PubMedCrossRef
125.
go back to reference Tanaka K, Shimada H, Matsuo K, et al. Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases. Surgery. 2004;136:650–9.PubMedCrossRef Tanaka K, Shimada H, Matsuo K, et al. Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases. Surgery. 2004;136:650–9.PubMedCrossRef
126.
127.
go back to reference Ariyan C, Wong D, Fong Y. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis (editorial). Ann Surg Oncol. 2007;14:3295–6.PubMedCrossRef Ariyan C, Wong D, Fong Y. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis (editorial). Ann Surg Oncol. 2007;14:3295–6.PubMedCrossRef
128.
go back to reference Yan TD, Chu F, Black D, et al. Synchronous resection of colorectal primary cancer and liver metastases. World J Surg. 2007;31:1496–501.PubMedCrossRef Yan TD, Chu F, Black D, et al. Synchronous resection of colorectal primary cancer and liver metastases. World J Surg. 2007;31:1496–501.PubMedCrossRef
129.
go back to reference Turrini O, Viret F, Guiramand J, et al. Strategies for the treatment of synchronous liver metastasis. Eur J Surg Oncol. 2007;33:735–40.PubMed Turrini O, Viret F, Guiramand J, et al. Strategies for the treatment of synchronous liver metastasis. Eur J Surg Oncol. 2007;33:735–40.PubMed
130.
go back to reference Thelen A, Jonas S, Benckert C, et al. Simultaneous versus staged liver resection of synchronous liver metastases from colorectal cancer. Int J Colorectal Dis. 2007;22:1269–76.PubMedCrossRef Thelen A, Jonas S, Benckert C, et al. Simultaneous versus staged liver resection of synchronous liver metastases from colorectal cancer. Int J Colorectal Dis. 2007;22:1269–76.PubMedCrossRef
131.
go back to reference Vassiliou I, Arkadopoulos N, Theodosopoulos T, et al. Surgical approaches of resectable synchronous colorectal liver metastases: timing considerations. World J Gastroenterol. 2007;13:1431–4.PubMed Vassiliou I, Arkadopoulos N, Theodosopoulos T, et al. Surgical approaches of resectable synchronous colorectal liver metastases: timing considerations. World J Gastroenterol. 2007;13:1431–4.PubMed
132.
go back to reference Weber JC, Bachellier P, Oussoultzoglou E, Jaeck D. Simultaneous resection of colorectal primary tumour and synchronous liver metastases. Br J Surg. 2003;90:956–62.PubMedCrossRef Weber JC, Bachellier P, Oussoultzoglou E, Jaeck D. Simultaneous resection of colorectal primary tumour and synchronous liver metastases. Br J Surg. 2003;90:956–62.PubMedCrossRef
133.
go back to reference Peeters KCMJ, Marijnen CAM, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years. Ann Surg. 2007;246:693–701.PubMedCrossRef Peeters KCMJ, Marijnen CAM, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years. Ann Surg. 2007;246:693–701.PubMedCrossRef
134.
go back to reference Martling A, Holm T, Johansson J, et al. The Stockholm II Trial on preoperative radiotherapy in rectal carcinoma. Cancer. 2001;92:896–902.PubMedCrossRef Martling A, Holm T, Johansson J, et al. The Stockholm II Trial on preoperative radiotherapy in rectal carcinoma. Cancer. 2001;92:896–902.PubMedCrossRef
135.
go back to reference Folkesson J, Birgisson H, Pahlman v, et al. Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23:5644–50.PubMedCrossRef Folkesson J, Birgisson H, Pahlman v, et al. Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23:5644–50.PubMedCrossRef
136.
go back to reference Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–23.PubMedCrossRef Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–23.PubMedCrossRef
137.
go back to reference Ahmed S, Shahid R, Zhu T, et al. Effect of surgical resection of primary tumor in advanced colorectal cancer (CRC) on outcome: a Canadian province’s experience. J Clin Oncol. 2008;26:abstr 15016. Ahmed S, Shahid R, Zhu T, et al. Effect of surgical resection of primary tumor in advanced colorectal cancer (CRC) on outcome: a Canadian province’s experience. J Clin Oncol. 2008;26:abstr 15016.
138.
go back to reference Ruo L, Gougoutas C, Paty PB, et al. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg. 2003;196:722–8.PubMedCrossRef Ruo L, Gougoutas C, Paty PB, et al. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg. 2003;196:722–8.PubMedCrossRef
139.
go back to reference Michel P, Roque I, Di Fiore F, et al. Colorectal cancer with non-resectable synchronous metastases: should the primary tumor be resected? Gastroenterol Clin Biol. 2004;28:434–7.PubMedCrossRef Michel P, Roque I, Di Fiore F, et al. Colorectal cancer with non-resectable synchronous metastases: should the primary tumor be resected? Gastroenterol Clin Biol. 2004;28:434–7.PubMedCrossRef
140.
go back to reference Kemeny NE, Capanu M, Fong Y, et al. Survival after resection of liver metastases from colorectal cancer with poor clinical risk factors using adjuvant systemic plus hepatic arterial therapy. J Clin Oncol. 2008;26:abstr 4076. Kemeny NE, Capanu M, Fong Y, et al. Survival after resection of liver metastases from colorectal cancer with poor clinical risk factors using adjuvant systemic plus hepatic arterial therapy. J Clin Oncol. 2008;26:abstr 4076.
141.
go back to reference Langer B, Bleiberg H, Labianca R, et al. Fluorouracil plus I-leucovorin versus observation after potentially curative resection of liver or lung metastases from colorectal cancer. Proc Am Soc Clin Oncol. 2002;21:abstr 149a. Langer B, Bleiberg H, Labianca R, et al. Fluorouracil plus I-leucovorin versus observation after potentially curative resection of liver or lung metastases from colorectal cancer. Proc Am Soc Clin Oncol. 2002;21:abstr 149a.
142.
go back to reference Lygidakis NJ, Sgourakis G, Vlachos L, et al. Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology. 2001;48:1685–91.PubMed Lygidakis NJ, Sgourakis G, Vlachos L, et al. Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology. 2001;48:1685–91.PubMed
143.
go back to reference Lorenz M, Müller HH, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases Arbeitsgruppe Lebermetastasen. Ann Surg. 1998;228:756–62.PubMedCrossRef Lorenz M, Müller HH, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases Arbeitsgruppe Lebermetastasen. Ann Surg. 1998;228:756–62.PubMedCrossRef
144.
go back to reference Welsh FKS, Tilney HS, Tekkis PP, et al. Safe liver resection following chemotherapy for colorectal liver metastases is a matter of timing. Br J Cancer. 2007;96:1037–42.PubMedCrossRef Welsh FKS, Tilney HS, Tekkis PP, et al. Safe liver resection following chemotherapy for colorectal liver metastases is a matter of timing. Br J Cancer. 2007;96:1037–42.PubMedCrossRef
145.
go back to reference Sahajpal A, Vollmer CM, Dixon E, et al. Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes. J Surg Oncol. 2007;95:22–7.PubMedCrossRef Sahajpal A, Vollmer CM, Dixon E, et al. Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes. J Surg Oncol. 2007;95:22–7.PubMedCrossRef
146.
go back to reference Tocchi A, Mazzoni G, Brozzetti S, et al. Hepatic resection in stage IV colorectal cancer: prognostic predictors of outcome. Int J Colorectal Dis. 2004;19:580–5.PubMedCrossRef Tocchi A, Mazzoni G, Brozzetti S, et al. Hepatic resection in stage IV colorectal cancer: prognostic predictors of outcome. Int J Colorectal Dis. 2004;19:580–5.PubMedCrossRef
147.
go back to reference Jaeck D, Bachellier P, Weber JC, et al. Surgical strategy in the treatment of synchronous hepatic metastases of colorectal cancers Analysis of a series of 59 operated on patients. Chirurgie. 1999;124:258–63.PubMedCrossRef Jaeck D, Bachellier P, Weber JC, et al. Surgical strategy in the treatment of synchronous hepatic metastases of colorectal cancers Analysis of a series of 59 operated on patients. Chirurgie. 1999;124:258–63.PubMedCrossRef
148.
go back to reference Jovine E, Biolchini F, Talarico F, et al. Major hepatectomy in patients with synchronous colorectal liver metastases: whether or not a contraindication to simultaneous colorectal and liver resection? Colorectal Dis. 2007;9:245–52.PubMedCrossRef Jovine E, Biolchini F, Talarico F, et al. Major hepatectomy in patients with synchronous colorectal liver metastases: whether or not a contraindication to simultaneous colorectal and liver resection? Colorectal Dis. 2007;9:245–52.PubMedCrossRef
149.
go back to reference Stojanović M, Stanojević G, Radojković M, et al. Safety of simultaneous colon and liver resection for colorectal liver metastases. Vojnosanit Pregl. 2008;65:153–7.PubMed Stojanović M, Stanojević G, Radojković M, et al. Safety of simultaneous colon and liver resection for colorectal liver metastases. Vojnosanit Pregl. 2008;65:153–7.PubMed
150.
go back to reference Zhang HZ, Dong SX, Zhou ZX, et al. Simultaneous liver and colorectal resection for synchronous colorectal liver metastasis. Zhonghua Wai Ke Za Zhi. 2007;45902–4. Zhang HZ, Dong SX, Zhou ZX, et al. Simultaneous liver and colorectal resection for synchronous colorectal liver metastasis. Zhonghua Wai Ke Za Zhi. 2007;45902–4.
151.
go back to reference Taniai N, Yoshida H, Mamada Y, et al. Outcome of surgical treatment of synchronous liver metastases from colorectal cancer. J Nippon Med Sch. 2006;73:82–8.PubMedCrossRef Taniai N, Yoshida H, Mamada Y, et al. Outcome of surgical treatment of synchronous liver metastases from colorectal cancer. J Nippon Med Sch. 2006;73:82–8.PubMedCrossRef
152.
go back to reference Sasanuma H, Yasuda Y, Mortensen FV, et al. Simultaneous colorectal and liver resections for synchronous colorectal metastases. Scand J Surg. 2006;95:176–9.PubMed Sasanuma H, Yasuda Y, Mortensen FV, et al. Simultaneous colorectal and liver resections for synchronous colorectal metastases. Scand J Surg. 2006;95:176–9.PubMed
153.
go back to reference Chua HK, Sondenaa K, Tsiotos GG, et al. Concurrent vs. staged colectomy and hepatectomy for primary colorectal cancer with synchronous hepatic metastases. Dis Colon Rectum. 2004;47:1310–6.PubMedCrossRef Chua HK, Sondenaa K, Tsiotos GG, et al. Concurrent vs. staged colectomy and hepatectomy for primary colorectal cancer with synchronous hepatic metastases. Dis Colon Rectum. 2004;47:1310–6.PubMedCrossRef
154.
go back to reference Martin R, Paty P, Fong Y, et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastases. J Am Coll Surg. 2003;197:233–42.PubMedCrossRef Martin R, Paty P, Fong Y, et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastases. J Am Coll Surg. 2003;197:233–42.PubMedCrossRef
155.
go back to reference Lyass S, Zamir G, Matot I, et al. Combined colon and hepatic resection for synchronous colorectal liver metastases. J Surg Oncol. 2001;78:17–21.PubMedCrossRef Lyass S, Zamir G, Matot I, et al. Combined colon and hepatic resection for synchronous colorectal liver metastases. J Surg Oncol. 2001;78:17–21.PubMedCrossRef
156.
go back to reference Fujita S, Akasu T, Moriya Y. Resection of synchronous liver metastases from colorectal cancer. Jpn J Clin Oncol. 2000;30:7–11.PubMedCrossRef Fujita S, Akasu T, Moriya Y. Resection of synchronous liver metastases from colorectal cancer. Jpn J Clin Oncol. 2000;30:7–11.PubMedCrossRef
157.
go back to reference Sugawara Y, Yamamoto J, Yamasaki S, et al. Estimating the prognosis of hepatic resection in patients with metastatic liver tumors from colorectal cancer with special concern for the timing of hepatectomy. Surgery. 2001;129:408–13.PubMed Sugawara Y, Yamamoto J, Yamasaki S, et al. Estimating the prognosis of hepatic resection in patients with metastatic liver tumors from colorectal cancer with special concern for the timing of hepatectomy. Surgery. 2001;129:408–13.PubMed
158.
go back to reference Bolton JS, Fuhrman GM. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg. 2000;231:743–51.PubMedCrossRef Bolton JS, Fuhrman GM. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg. 2000;231:743–51.PubMedCrossRef
159.
go back to reference Doko M, Zovak M, Ledinsky M, et al. Safety of simultaneous resections of colorectal cancer and liver metastases. Coll Antropol. 2000;24:381–90.PubMed Doko M, Zovak M, Ledinsky M, et al. Safety of simultaneous resections of colorectal cancer and liver metastases. Coll Antropol. 2000;24:381–90.PubMed
160.
go back to reference Scheele J, Stangl R, Altendorf-Hofmann A, et al. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery. 1991;110:13–29.PubMed Scheele J, Stangl R, Altendorf-Hofmann A, et al. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery. 1991;110:13–29.PubMed
161.
go back to reference Vogt P, Raab R, Ringe B, Pichlmayr R. Resection of synchronous liver metastases from colorectal cancer. World J Surg. 1991;15:62–7.PubMedCrossRef Vogt P, Raab R, Ringe B, Pichlmayr R. Resection of synchronous liver metastases from colorectal cancer. World J Surg. 1991;15:62–7.PubMedCrossRef
162.
go back to reference Jatzko G, Wette V, Muller M, et al. Simultaneous resection of colorectal carcinoma and synchronous liver metastases in a district hospital. Int J Colorect Dis. 1991;6:111–4.CrossRef Jatzko G, Wette V, Muller M, et al. Simultaneous resection of colorectal carcinoma and synchronous liver metastases in a district hospital. Int J Colorect Dis. 1991;6:111–4.CrossRef
Metadata
Title
Synchronous Colorectal Liver Metastases: Is It Time to Reconsider Traditional Paradigms of Management?
Authors
Srinevas K. Reddy, MD
Andrew S. Barbas, MD
Bryan M. Clary, MD
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 9/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0372-1

Other articles of this Issue 9/2009

Annals of Surgical Oncology 9/2009 Go to the issue

CONTROVERSIES IN THE MANAGEMENT OF HEPATIC COLORECTAL METASTASES

The Role of Preoperative Chemotherapy in Patients with Resectable Colorectal Liver Metastases

Controversies in the Management of Hepatic Colorectal Metastases

Controversies in the Management of Hepatic Colorectal Metastases